# Phase 5d CBC06 Evidence Review Completion — 2026-08-10

**Status:** complete — external evidence packet prepared; expert sign-off pending.

## Deliverable

`validation_packets/CBC06_CKRT_NET_ULTRAFILTRATION_EVIDENCE_REVIEW_2026-08-10.md`

## Evidence disposition

External evidence supports pediatric ECMO/CKRT fluid-removal use, explicit prescribed-versus-delivered ultrafiltration accounting, and the directional risk that net fluid removal can reduce circulating volume/hemodynamic reserve.

The exact simulator gate `CKRT selected + Qb > 0` is retained as a system-consistency rule and remains an expert workflow-review item, not a universal device/clinical claim.

The canonical Qb, net-UF rate, durations, recovery tolerances, and hemodynamic magnitudes remain regression-only. No solute-clearance or dialysis-dose claim is added.

## Bookkeeping correction

CBC06 predated Phase 2b and still said learner CKRT controls were absent. Phase 2b made Qb/net-UF learner-operable. Contract documentation/JSON and the capability-matrix CBC06 row were corrected accordingly. No CBC06 behavior or physiology changed.

## Source scope

Phase 5d CBC06 is evidence/documentation/test work only. No `src/` file is intentionally changed.

## Roadmap

FIX_MAP v4 remains untouched. Phase 5d continues with the remaining Priority-A evidence packets.

## Verification

- CBC06 evidence + contract + Phase 2b controls + fixed-shunt behavior: **41/41 passed**.
- Phase-5d CBC01/CBC02/CBC06 evidence consistency: **17/17 passed**.
- Exact repository collection after adding the new evidence tests: **450 tests**.
- Capability matrix: **88 rows**, CSV/JSON mirrors identical.
- Embedded Phase-1b backing data remains **79 actions / 36 complications / 28 scenario IDs**.
- Validation queue remains **11 CBCs**.
- `src/` diff versus v0.20.2: **none**.
